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Abstract
The SW480 cell line is derived from a human colon adenocarcinoma, and SW620 cells are derived from a lymph node
metastasis of the same patient. We have previously shown that lupulone induces apoptosis in SW480 cells, through
a cross talk between the TRAIL–death receptor pathway and the mitochondrial apoptotic pathway. In SW620 cells,
lupulone induced apoptosis only through TRAIL–death receptor activation. Both cell lines exhibit the same p53 muta-
tions. Because p53 plays a central role in the response to cellular stresses by upregulating the transcription of several
genes controlling apoptosis, we aimed to study the involvement of p53 on lupulone-triggered apoptosis. Our data
show that in SW620 cells, lupulone upregulated p53 gene expression and caused a cloistering of p53 in the nucleus,
allowing p53 to play a proapoptotic role by activating the TRAIL–death receptor pathway. In contrast, in lupulone-
treated SW480 cells, p53 was translocated to the cytoplasm where it initiated a survival response associated with
the up-regulation of antiapoptotic Bcl-2 and Mcl-1 proteins in an attempt to preserve mitochondrial integrity. These
prosurvival effects of p53 in lupulone-treated SW480 cells were reversed by pifithrin-α, an inhibitor of p53 function,
which caused a blocking of p53 in the nucleus leading to the down-regulation of Bcl-2 and Mcl-1, the up-regulation
of proapoptotic Bax protein and TRAIL–death receptors leading to enhanced cell death. Our data support different
functions of the same mutated p53 in colon adenocarcinoma and derived metastatic cells in response to the chemo-
preventive agent lupulone.
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Introduction
The p53 protein plays a central role in the response to a wide range of
cellular stresses including DNA damage. Activated p53 leads to cell
cycle arrest, cell senescence or apoptosis [1]. This protein can act like
a transcription factor and upregulate the transcription of several genes
implicated in the control of cell proliferation or apoptosis [2]. However,
it was recently reported that the p53 protein was also able to modulate
the intrinsic mitochondrial apoptotic pathway through interactions
with members of the Bcl-2 family [3,4].
Most human cancers, including colon cancer, exhibitmutations of the
p53 gene and altered protein function. The SW480 cell line is derived
from a primary colon adenocarcinoma obtained from a 50-year-oldwhite
male, and the SW620 cell line is derived from a lymph node metastasis
of the same patient. Therefore, these two related cell lines represent an
interesting in vitro model of the progression of colon cancer from a pri-
mary tumor to its metastatic spread [5]. Both cell lines exhibit a mutated
p53 gene with a guanosine-to-adenosine mutation at codon 273, and
a cytosine-to-thymidine mutation at codon 309 resulting, respectively,
in arginine-to-histidine and proline-to-serine substitutions in the p53
protein [6]. It was reported that despite these mutations, depending on
the cellular stress, the p53 protein may retain its ability to induce DNA
repair mechanisms, cell cycle arrest, and apoptosis [7,8].
Lupulone, a bitter acid of hops (Humulus lupulus L.), consists of a
mixture of the isomers n-, co-, and ad-lupulones. We have previously
shown that lupulone induces apoptosis in SW480 and SW620 cells
by activating TRAIL–death receptor signaling pathways. In SW480
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cells, lupulone induced a cross talk between the extrinsic and intrinsic
apoptotic pathways involving mitochondrial alterations. In the metas-
tatic SW620 cells, lupulone induced an activation of the extrinsic
apoptotic pathway through TRAIL–death receptor activation [9]. To
gainmore insight into themolecular mechanisms triggered by lupulone,
particularly in TRAIL-resistant SW620 cells and the mitochondrial
implication observed only in SW480 cells, we aimed to investigate
the effects of lupulone on p53 functions in both cell lines. Indeed, ac-
tivation of p53 may regulate DR4, DR5 TRAIL–death receptor, and/
or Bcl-2 family member expression, such as Bcl-2 or Bax. Moreover,
by transcription-independent mechanisms, the p53 protein may be
translocated to the mitochondria, where it may interact with Bax, Bcl-2,
or Bcl-XL and induce the release of cytochrome c [10,11].
Materials and Methods
Materials
Lupulone was obtained from an industrial by-product (Brasseries
Kronenbourg, Strasbourg, France) and was isolated following the pro-
cedure described previously [12]. Reverse transcription–polymerase
chain reaction (RT-PCR) was performed by using different kits: RNeasy
Mini kit, High-Capacity cDNA Archive kit, TaqMan Gene expression
for primer of p53, TaqMan Universal PCR Master Mix, and ABI Prism
7500 Sequence Detection System, which were obtained from Applied
Biosystems (Foster City, CA). Primary antibodies to p53, DR4, and
DR5 were obtained from Alexis Biochemicals (Lausen, Switzerland).
Primary antibodies to phospho-p53 (Ser-15) and phospho-p53 (Ser-
392) were obtained from Abcam (Paris, France). An antibody to
p53 conjugated with fluorescein isothiocyanate (FITC), which was used
for p53 detection by flow cytometry, and the p53 chemical inhibitor
pifithrin-α (PFT-α) were obtained from Calbiochem, Merck Chemicals
(Darmstadt, Germany). Antibodies to Bcl-2 conjugated with FITC and
primary antibodies toMcl-1 and Bax were obtained fromBDBiosciences
(Erembodegem, Belgium).
Cell Culture
SW480 and SW620 cells were obtained from the European Collec-
tion of Animals Cell Culture (Salisbury, UK). Cells were maintained
in Dulbecco’s modified Eagle medium containing 25 mM glucose and
supplemented with 10%heat-inactivated (56°C) horse serum, 100U/ml
penicillin, 100 μg/ml streptomycin, and 1% nonessential amino acids
(Invitrogen Corp, Cergy Pontoise, France) and kept at 37°C in a humidi-
fied atmosphere with 5% CO2. For experiments after trypsinization
(0.5% trypsin/2.6 mM ethylenediamine tetraacetic acid), cells were
seeded at 1 × 106 cells in culture dishes (100-mm internal diameter).
The culture medium was Dulbecco’s modified Eagle medium supple-
mented with 3% heat-inactivated horse serum, 100 U/ml penicillin,
100 μg/ml streptomycin, 5 μg/ml transferrin, 5 ng/ml selenium, 10 μg/
ml insulin, and 1% nonessential amino acids (Invitrogen Corp).
Analysis of p53 mRNA Level by Real-time RT-PCR
To determine expression of p53 mRNA, extraction of total RNA
and analysis by real-time RT-PCR were performed. Total RNA was
extracted using the RNeasy Mini kit (QIAGEN, VWR, Copenha-
gen, Denmark) following the manufacturer’s instructions. The High-
Capacity cDNA Archive kit (Applied Biosystems) was used to reverse
transcribe RNA (1 μg) in 20 μl of reaction mix, and the measure-
ments of the transcription levels of the selected genes were performed
with TaqMan Gene Expression assays (protein p53, Hs00153349;
Applied Biosystems). β-Actin was assigned as an endogenous control
(cat. no. Hs99999903; Applied Biosystems). Real-time RT-PCR was
performed with TaqMan Universal PCR Master Mix and ABI Prism
7500 Sequence Detection System (Applied Biosystems Sequence de-
tector; Applied Biosystems) in triplicate wells. Data were analyzed with
a comparative threshold cycle (ΔCT) method. This method is used to
determine the values of Δcycle threshold (ΔC t) by normalizing the
average C t value of each treatment with value of each opposite endoge-
nous control (β-actin). Then, calculation of 2−ΔΔC t of each treatment
and statistical analysis were performed as described by Livak and
Schmittgen [13].
Detection of p53 Expression in Cells by Flow Cytometry
Cells were treated with lupulone (40 μg/ml) and harvested by
trypsinization at 24 and 48 hours. Cell pellets were washed with
phosphate-buffered saline (PBS) and were fixed with a solution of
PBS containing 4% paraformaldehyde for 1 hour at 4°C in the dark.
Cell pellets were washed with a solution of PBS/BSA 0.2%/Tween
0.5% and were incubated with FITC-conjugated mouse antihuman
p53 antibody (Calbiochem) or FITC-conjugated mouse IgG1 mono-
clonal isotype control antibody (BD Biosciences) for 1 hour at 4°C in
the dark. After washing with the solution of PBS/BSA 0.2%/Tween
0.5%, cells were resuspended in PBS (37°C), and the fluorescence
(515 nm) of 10,000 events per sample was analyzed by FACScan
and CellQuest Software (BD Biosciences).
Detection of p53 Protein Expression by Western Blot Analysis
Cells (8 × 106) were treated with PFT-α (30 μM) and/or lupulone
(40 μg/ml) and harvested at 24 and 48 hours. Nuclear, mitochondrial,
and cytosolic fractions were isolated from cells using the Nuclear Ex-
tract Kit and Mitochondrial Fractionation Kit (ActiveMotif Europe,
Rixensart, Belgium), and the protein content of each fraction was mea-
sured with the Lowry method. Western blot analysis was performed as
previously described [9] with a protein load of 50 μg.
Cell Death Analysis after p53 Inhibition
SW480 or SW620 cells (1 × 106 cells) were seeded in culture dishes
and pretreated with a p53 inhibitor, PFT-α (30 μM;Merck Chemicals)
1 hour before lupulone treatment (40 μg/ml). Cells were harvested by
trypsinization at 24 and 48 hours, washed with PBS, centrifuged, and
fixed with 1 ml methanol-PBS (9:1 vol./vol.) during a 1- to 3-hour
incubation at −20°C. Cells were washed twice in PBS and resuspended
in 200 μl of PBS containing 0.25 μg/ml RNase A and 0.1 mg/ml
propidium iodide (Sigma Aldrich, Munchen, Germany). After incu-
bating in the dark at 37°C for 30 minutes, the fluorescence of cells
(10,000 events) was analyzed by flow cytometry using CellQuest soft-
ware (FACScan; BD Biosciences).
Expression of TRAIL Receptors DR4 and DR5 after
p53 Inhibition
Cells were pretreated for 1 hour with PFT-α at 30 μM and treated
with lupulone (40 μg/ml) for 24 and 48 hours. After trypsinization,
cell pellets were washed with PBS and incubated with monoclonal
mouse antihuman antibodies to TRAIL-R1 (DR4; 1:100) or TRAIL-
R2 (DR5; 1:100; Alexis Biochemicals, Lausen, Switzerland) for 30min-
utes at 4°C. Cells were washed twice with PBS and incubated with
FITC-conjugated goat antimouse IgG1 antibody (1:50; AbD Serotec,
Düsseldorf, Germany) or with FITC-conjugated mouse IgG1 mono-
clonal isotype control antibody (1:50; BD Biosciences) for 30 minutes
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at 4°C in the dark. After washing with PBS, cells were resuspended in
PBS and the fluorescence of 10,000 events per sample (515 nm) was
analyzed by FACScan using CellQuest software (BD Biosciences).
Expression of Bcl-2, Mcl-1, and Bax Proteins after
p53 Inhibition
SW480 cells were pretreated for 1 hour with PFT-α at 30 μM and
treated with lupulone (40 μg/ml) for 24 and 48 hours. Cells were
harvested by trypsinization and processed for the fixation (PBS/para-
formaldehyde 4%) and permeabilization (PBS/BSA 0.2%/Tween
0.5%) steps. For Bcl-2 protein detection, cells were labeled directly with
20 μl of FITC-conjugated mouse antihuman Bcl-2 monoclonal anti-
body or FITC-conjugated mouse IgG1 monoclonal Isotype control
antibody (BD Biosciences) for 30 minutes at 4°C in the dark. For Mcl-1
and Bax detection, cells were incubated with rabbit antihuman Bax
polyclonal antibody or rabbit antihuman Mcl-1 polyclonal antibody
(1:100; BD Biosciences) for 30 minutes at 4°C. After washing twice,
FITC-conjugated swine antirabbit F(ab′)2 antibody was added (1:10;
Abcam) for 30minutes at 4°C in the dark. After washing twice in permea-
bilization buffer, the fluorescence of 10,000 cells was analyzed using a
FACScan flow cytometer and CellQuest software (BD Biosciences).
Statistical Analysis
All data were presented as mean ± SE from three independent experi-
ments. Significant differences between control and treated groups were
evaluated by one-way ANOVA analysis, Student’s t-test, or the Student-
Newman-Keuls multiple comparison test was used to determine the
significance of differences between data.
Results
Expression of p53 mRNA and Protein after
Lupulone Treatment
We reported previously that lupulone activated apoptosis in SW480
and SW620 cells through TRAIL–death receptor signaling pathways. In
addition, we showed a specific activation of the intrinsic mitochondrial
pathway only in SW480 cells [9]. To gain more insight into these pro-
cesses, p53 mRNA and protein expression was assessed using real-time
RT-PCR and flow cytometry.
The p53 mRNA expression increased significantly in SW620 cells
after lupulone treatment in a time-dependent manner; a significant
increase with time was observed in the amount of p53 transcripts (by
three-fold at 24 hours and by eight-fold at 48 hours) compared with
untreated control cells (Figure 1A). In lupulone-treated SW480 cells,
the amount of p53 transcripts was significantly lower when compared
with the level detected in SW620 cells and increased only marginally
with time (by 1.5-fold at 24 hours and by 2-fold at 48 hours). However,
a time-dependent increase in p53 protein expression was observed after
lupulone treatment in both SW620 and SW480 cell lines (Figure 1B).
These data suggested that in SW620 cells, p53 expression was mainly
regulated at the transcriptional level, whereas in SW480 cells, the in-
crease in p53 expression did not result from an up-regulation of p53
gene transcription but rather from posttranscriptional events. Neverthe-
less, it was clear that in both cell lines, lupulone was able to significantly
enhance p53 protein expression.
Activation of the p53 Protein after Lupulone Treatment
Activation of the p53 protein is characterized by phosphorylation at
specific sites, such as serine-15 or serine-392 [14,15]. UsingWestern blot
analysis, we measured the amount of total p53 protein and phosphory-
lated p53 protein at serine-15 and serine-392 after 24 and 48 hours
of lupulone treatment (Figure 2). In both cell lines, we observed a
strong increase in p53 protein phosphorylation at serine-392 in a
time-dependent manner, as well as an increase in the amount of total
p53 protein (Figure 2). Concerning p53 protein phosphorylation at
serine-15, lupulone induced an important increase after 48hours of treat-
ment in SW620 cells, but this effect was weak in SW480 cells.
Intracellular Localization of the p53 Protein in SW480 and
SW620 Cells
Drugs may cause a stress signal favoring the activation and the trans-
location of p53 from the nucleus to the cytoplasm by transcription-
independent mechanisms [4]. UsingWestern blot analysis, we compared
the amount of p53 present in the nucleus, cytosol, and mitochondria
after lupulone treatment (Figure 3). After 48 hours of lupulone treat-
ment, an increased amount of p53 was found in the nucleus of both cell
lines (Figure 3A). However, an accumulation of p53 was observed in the
cytosol and mitochondria of lupulone-treated SW480 cells, and such an
Figure 1. Expression of p53mRNAand protein in SW480 andSW620
cells. Cells were treated with DMSO 0.1% ± lupulone (40 μg/ml) for
24 and 48 hours. (A) Real-time quantitative measurement of p53
mRNA levels represented as the fold change over untreated cells.
Data are calculated with the comparative cycle threshold method
[13] and correspond to themean value ± SE of at least three separate
experiments. Columns not sharing the same superscript letter differ
significantly: a≠b≠c P < .05. (B) Determination of p53 protein expres-
sion by flow cytometry. At each time point, cells were harvested and
stained with FITC-conjugated antihuman p53 antibody. Increased
green fluorescence was measured by flow cytometry, and data are
represented by histograms as the percent of cells expressing p53
protein. Data are the mean value ± SE of at the least three separate
experiments. Columns not sharing the same superscript letter differ
significantly: a≠b≠c≠d P < .05.
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effect was not found in SW620 cells where p53 was retained in the
nucleus (Figure 3, B and C). These data indicate that in SW480 cells,
but not in SW620 cells, lupulone treatment favored a translocation of
p53 protein from the nucleus to the cytoplasm.
Effect of p53 Inhibition on SW480 and SW620 Cell Death
To determine the role of p53 in lupulone-triggered apoptosis,
cells were treated with PFT-α (30 μM), a reversible inhibitor of p53-
responsive genes which blocks p53-mediated apoptosis [16,17]. Cells
were exposed to the inhibitor 1 hour before lupulone (40 μg/ml) treat-
ment. The amount of dead or dying hypodiploid cells was determined
with propidium iodide staining by flow cytometry, and these cells were
detected in the sub-G0/G1 region [18,19]. In SW620 cells, PFT-α
caused a significant (P < .05) diminution of cell death after lupulone
treatment (Figure 4). Surprisingly, in lupulone-treated SW480 cells
exposed to the p53 inhibitor, a huge increase in the amount of hypo-
diploid cells was observed. Indeed, after 48 hours of treatment with
lupulone + PFT-α, the amount of cells in the sub-G0/G1 region was in-
creased by 40% relative to SW480 cells treated with lupulone used as a
single drug (Figure 4). Our data strongly suggested that p53 may act
like a cell survival factor in lupulone-treated SW480 cells, and such an
effect was not observed for the metastatic SW620 cells.
PFT-α Hindered p53 Translocation in Lupulone-Treated
SW480 Cells
PFT-α inhibits p53 transcriptional activity and has been reported to
block p53 translocation from nucleus to cytosol through a transcription-
independent manner [20]. Using Western blot analysis, we compared
the amount of p53 present in nucleus and cytosol, after pretreatment
with PFT-α (30 μM). In lupulone-treated SW480 cells, PFT-α blocked
p53 in the nucleus and reduced the amount of p53 in the cytosolic
Figure 2. Effect of lupulone on the protein levels of total p53 and of phosphorylated (phospho-) p53. The amount of total p53 protein,
phospho-p53 (Ser-392) and phospho-p53 (Ser-15), was analyzed by Western blot analysis and corresponded to a band of 53 kDa. β-Actin
was used as an internal control. Determination of p53 protein amounts was assessed after protein extraction from SW620 and SW480
cells after 24 and 48 hours of lupulone treatment. Data are representative of at least three independent experiments. The numbers at the
bottom of each lane indicate the fold increase relative to the untreated control.
Figure 3. Intracellular localization of p53 protein in SW480 and
SW620 cells. The amount of p53 protein was analyzed by Western
blot analysis and corresponded to a band of 53 kDa. β-Actin was
used as an internal control. Determination of amount of p53 protein
was measured in the nuclear fraction (A), the cytosolic fraction (B),
and in themitochondrial fraction (C) of SW620 and SW480 cells after
lupulone treatment for 48 hours. Data are representative of at least
three independent experiments. The numbers at the bottom of each
lane indicate the fold increase relative to the untreated control.
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fraction (Figure 5A). These data demonstrated that PFT-α hindered the
translocation of p53 from the nucleus to the cytosol.
Effect of p53 Inhibition on the Expression of Bcl-2
Family Members
It has been reported that, by a transcription-independent manner and
after translocation from nucleus to the cytosol or mitochondria, p53 can
form heterocomplexes with Bcl-2 or Mcl-1 leading to the activation of
Bax, inducing mitochondrial disruption [4,10]. Lupulone treatment
induced a significant increase of Bax protein in a time-dependent manner
(Figure 5B), leading to activation of the intrinsic apoptotic pathway
through the disruption of the mitochondria [9]. Here we show that
p53 inhibition by PFT-α induced a further significant increase of Bax
protein expression associated with a down-regulation of the Bcl-2 and
Mcl-1 survival factors (Figure 5B).
Regulation of TRAIL–Death Receptors Expression by p53
Cell surface expression of TRAIL-DR4 and -DR5 death receptors
was measured after inhibition of p53 functions by PFT-α in lupulone-
treated SW620 and SW480 cells. Up-regulation of TRAIL–death re-
ceptors by p53, more specifically DR5 expression, has been reported
during the activation of apoptosis [21,22]. In lupulone-treated SW620
cells, p53 inhibition by PFT-α caused a significant reduction in the
expression of DR5 receptor, but DR4 receptor expression was only
slightly affected (Figure 6A). These data suggested that in SW620 cells,
p53 seemed to act as a proapoptotic regulator by enhancing DR5 ex-
pression in response to lupulone treatment. Moreover, the specific
regulation of DR5 expression by p53 without affecting DR4 death
receptor expression may explain the limited decrease of cell death ob-
served after p53 inhibition. Conversely, in lupulone-treated SW480
cells, the inhibition of p53 by PFT-α induced a significant increase
of both DR4 andDR5 expression (Figure 6B). These data also support
the view that, in lupulone-treated SW480 cells, p53 plays the role of
a cell survival factor.
Discussion
After cells are exposed to drugs that initiate a stress signal, it has been
reported that p53 activates different cellular responses, including DNA
repair, cell cycle arrest, and/or apoptosis [23,24]. In both the SW480
cells obtained from a human colon adenocarcinoma and in the derived
metastatic SW620 cells, p53 is mutated in the same position in codon
273 and codon 309, resulting in arginine-to-histidine and proline-to-
serine substitutions in the p53 protein [5]. Despite these mutations,
p53 can be activated in these cell lines and modulate cell growth or
death [6,25]. In both SW480 and SW620 cells, we observed an up-
regulation of p53 mRNA and protein by lupulone when compared with
untreated cells. However, the amount of p53 transcripts was far lower
in SW480 cells compared with the amount detected in SW620 cells.
In the latter, our data indicated that lupulone caused an up-regulation
of p53 mainly at the transcriptional level, whereas in SW480 cells, the
increase in p53 expression resulted mainly from a posttranscriptionalFigure 4. Effect of p53 inhibition on SW620 and SW480 cell death.
Cells were pretreated with p53 inhibitor, PFT-α (30 μM), 1 hour before
lupulone treatment (40 μg/ml) for 24 and 48 hours. At each time point,
cells were harvested, stained with propidium iodide, and analyzed
by flow cytometry. The percentage of hypodiploid cells present in
the sub-G0/G1 region is represented as a histogram and corresponds
to themean value±SEof at the least three separate experiments. For
each cell line, columns not sharing the same superscript letter differ
significantly, a≠b≠c≠d≠e P < .05.
Figure 5. Effect of PFT-α on p53 translocation and Bcl-2, Mcl-1, and
Bax expression in SW480 cells. Cells were pretreated with p53 in-
hibitor, PFT-α (30 μM), 1 hour before lupulone treatment (40 μg/ml)
for 24 and 48 hours. (A) inhibition of p53 translocation by PFT-α. The
amount of p53 protein was analyzed by Western blot analysis and
corresponded to a band of 53 kDa. β-Actin was used as an internal
control. The amount of p53 protein was determined in the nuclear
fraction and in the cytosolic fraction of SW480 cells after lupulone
treatment for 48 hours. Data are representative of at least three
independent experiments. The number at the bottom of each lane
indicates the fold increase relative to the untreated control. (B) Ex-
pression of Bcl-2, Mcl-1, and Bax proteins. At each time point, cells
were harvested, fixed, and permeabilized. After washing, cells were
incubatedwith the appropriate antibody (seeMaterial andMethods).
Increased green fluorescence was measured by flow cytometry,
and data are represented by histograms as the percentage of cells
expressing Bcl-2, Mcl-1, or Bax proteins. Data are the mean value ±
SE of at the least three separate experiments. At each period (24 or
48 hours), columns not sharing the same superscript letter differ
significantly: a≠b≠c≠d≠e or a′≠b′≠c′≠d′≠e′≠f′≠g′ P < .05.
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regulatorymechanism. After lupulone treatment, p53 was phosphorylated
at serine-392 in both cell lines, but the phosphorylation of serine-15 was
specifically increased in SW620 cells and not in SW480 cells. Several
studies have reported that phosphorylation at serine-15 prevents p53 from
being exported from the nucleus and favors p53-controlled transcriptional
activity [26,27]. Thus, the phosphorylation of p53 at serine-15 induced
by lupulone in SW620 cells may favor the observed activation of the ex-
trinsic apoptotic pathway through the previously reported [9] enhanced
transcription of TRAIL-DR4 and -DR5 death receptors. In fact, our
present data show that in the metastatic SW620 cells, p53 upregulated
only the expression of the TRAIL-DR5 death receptor without affecting
DR4 expression. This may explain why the inhibition of p53 by PFT-α,
an inhibitor of p53-mediated transcription known to block p53-related
apoptosis [28,29], caused only a moderate but significant (P < .05) reduc-
tion of SW620 cell death after lupulone treatment. Thus, in SW620
cells, p53 plays a proapoptotic role after lupulone treatment by regulat-
ing the expression of target genes, like DR5, resulting in an enhanced
apoptotic response after lupulone treatment (Figure 7A).
In contrast to SW620 cells, the apoptotic responses of SW480 cells
to lupulone are different and involved, as previously reported [9],
a cross talk between the extrinsic (death receptor) and the intrinsic
(mitochondrial) apoptotic pathways through Bid protein cleavage lead-
ing to mitochondrial disruption. In addition, we show here that in
lupulone-treated SW480 cells, in contrast to what was observed in
SW620 cells, p53 was translocated in the cytosol. It has been described
that, by a transcription-independent manner, p53 can be translocated
from the nucleus to the cytosol or mitochondria and can form protein
heterocomplexes with Bcl-XL, Bcl-2, or Mcl-1 leading to the activation
of Bax or Bad and, consequently, to mitochondrial disruption and
release of cytochrome c to promote cell death [4,10,11,30]. Thus,
the observed increase of p53 in the cytoplasm of lupulone-treated
Figure 6. Analysis of DR4/DR5 receptor expression after p53 in-
hibition. Cellswere pretreatedwith p53 inhibitor, PFT-α (30μM), 1 hour
before lupulone treatment (40 μg/ml) for 24 and 48 hours. At each
time point, cells were harvested, stained with monoclonal antibodies
against TRAIL DR4 or DR5 receptor, and, after washing, incubated
with FITC-conjugated goat antimouse IgG1 antibody. Increased green
fluorescence was measured by flow cytometry, and data are repre-
sented by histograms as the percentage of cells expressing DR4 or
DR5 receptors (A) in SW620 cells and (B) in SW480 cells. Data are
the mean value ± SE of at the least three separate experiments. At
each period (24 or 48 hours), columns not sharing the same super-
script letter differ significantly: a≠b≠c≠d≠e or a′≠b′≠c′≠d′≠e′ P < .05.
Figure 7. Schemes of the opposing responses of p53 after lupulone
treatment in SW620 and SW480 cells. (A) In SW620 cells, lupulone
induced apoptosis by activating the extrinsic apoptotic signaling path-
way involving TRAIL-DR4/DR5 receptors and caspases activation [9].
In these cells, p53 plays a proapoptotic role. Lupulone upregulated
p53 transcription and protein expression; p53 accumulated in the
nucleus, where it enhanced the transcription of TRAIL-DR5 gene,
which amplified the apoptotic response triggered by lupulone. In-
hibition of p53 by PFT-α caused only a limited decrease of cell death
because TRAIL-DR4 receptor expression remained unaffected by p53
activation. (B) In SW480 cells, lupulone induced apoptosis by acti-
vating both the extrinsic and intrinsic (mitochondrial) apoptotic sig-
naling pathways involving TRAIL-DR4/DR5 receptors and caspases
activation [9]. As opposed to SW620 cells, p53 played the role of a
survival factor in SW480 cells. Indeed, activation of p53 by lupulone
caused a down-regulation of TRAIL-DR4 and -DR5 expression and a
translocation of p53 from the nucleus to the cytosol associated with
an up-regulation of the antiapoptotic Bcl-2 and Mcl-1 proteins favor-
ing a protective effect on mitochondrial function. These prosurvival
effects of p53 were reversed by PFT-α, which caused a blocking of
p53 in the nucleus enhancing its proapoptotic effects.
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SW480 cells may participate in mitochondrial disruption. Surprisingly,
after lupulone treatment, the inhibition of p53 function by PFT-α ini-
tiated increased cell death associated with an up-regulation of TRAIL
DR4/DR5 death receptors and of the proapoptotic Bax protein con-
comitantly with the down-regulation of mitochondrial Bcl-2 and
Mcl-1 survival factors. These data taken together showed that in-
hibition of p53 by PFT-α increases apoptosis induced by lupulone in
SW480 cells. In these cells, p53 might upregulate the expression of
genes whose products reduced the apoptotic signaling and favored cell
survival. The inhibition of p53 function in lupulone-treated SW480
cells by PFT-α caused a blocking of p53 in the nucleus associated with
a correlated reduced amount in the cytosol, confirming the already-
reported ability of PFT-α to reduce the translocation of p53 from
the nucleus to the cytoplasm [18,31]. In lupulone-treated SW480 cells,
p53 was weakly phosphorylated at the level of serine-15 (as compared
with SW620 cells) allowing the observed translocation of p53 from the
nucleus into the cytoplasm where p53 might exert a protective effect
on mitochondrial function [26,27]. This is in accordance with our
present data showing that the p53 inhibitor PFT-α by blocking p53
in the nucleus enhanced the apoptotic response induced by lupulone.
Our present report indicates that p53, which carries the same muta-
tions in both cell lines [6], plays opposing roles in the death signaling
pathways triggered by lupulone in SW480 cells and in the derived me-
tastatic SW620 cells (Figure 7). Our data show that in lupulone-treated
SW620 cells, p53 is acting in a transcription-dependent manner and
plays the role of apoptotic enhancer by favoring the apoptotic response
through the activation of the TRAIL–death receptor pathway. Con-
versely, in lupulone-treated SW480 cells, p53 favors cell survival in an
attempt to preserve mitochondrial integrity. However, the prosurvival
signals activated by p53 in cells exposed to lupulone is counterbalanced
by the previously described [9] overwhelming apoptotic signaling cas-
cade activated by lupulone. The present data support the view that
p53 plays only a marginal role in the regulation of lupulone-triggered
apoptosis but demonstrate that the same p53 protein may exert oppo-
site functions (either as an apoptotic or survival factor) in a primary
colon adenocarcinoma and in the derived metastatic cells.
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